Actually it was strong clinical trial revenue. It was a legitimate contract cancelled through no fault of CDX. I dont see that as spin except to say, if there is no follow up clinical contracts in the near term it would look more like a one off rather than recurring revenue (through other contracts) It looks like they still have a relationship with clinichain so accept that its good news with money in the bank and lets hope they have a pipeline ready to execute.
That would be a good question for the AGM if anyone is attending. They have mentioned before about strong clinical pipeline I think in the tens of millions, I'd like to know where we are with that.
Other wise, low expenditure and money in the bank, onwards and upwards
CDX Price at posting:
12.1¢ Sentiment: Buy Disclosure: Held
